ARID1A and cancer: One approach utilising synthetic‐lethal approaches for targeting ARID1A‐deficient cancers with the ATR inhibitor ceralasertib with or without the  PARP (poly ADP ribose polymerase) inhibitor olaparib is being assessed in the ATARI phase II international proof‐of‐concept clinical trial.